• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Synergy CHC Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits

    6/4/25 8:37:50 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care
    Get the next $SNYR alert in real time by email
    false 0001562733 0001562733 2025-05-30 2025-05-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): May 30, 2025

     

    SYNERGY CHC CORP.

    (Exact name of registrant as specified in its charter)

     

    Nevada   001-42374   99-0379440
    (State or Other Jurisdiction   (Commission File Number)   (IRS Employer
    of Incorporation)       Identification No.)

     

    865 Spring Street, Westbrook, Maine   04092
    (Address of principal executive offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: (902) 237-1220

     

     

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock   SNYR   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 1.01 Entry into a Material Definitive Agreement.

     

    On May 30, 2025, Synergy CHC Corp. (the “Company”) entered into a term loan credit agreement (the “Credit Agreement”) with ACP Agency, LLC (“ACP”). The Credit Agreement consists of a $15.0 million term loan (the “Term Loan”), up to $2.5 million in a committed delayed draw facility (the “Delayed Draw Facility”), and up to $2.5 million in an uncommitted term loan incremental facility (the “Incremental Facility”), which facilities are secured by all of the assets of the Company and certain of its subsidiaries; including, without limitation, a pledge of the Company’s equity interests in its subsidiaries and their respective rights to intellectual property. Further, the obligations of the Company under the Credit Agreement are guaranteed by the Company and certain of its subsidiaries. The proceeds of the Term Loan are to be used to repay existing indebtedness of the Company, pay related fees and transaction costs, and provide working capital to the Company. The proceeds of the Delayed Draw Facility are to be used to pay off all indebtedness owed by the Company pursuant to certain settlement agreements. All capitalized words used but not defined herein have the meanings assigned in the Credit Agreement.

     

    The Credit Agreement has customary representations, warranties and covenants including restrictions on indebtedness, liens, restricted payments and dividends, investments, asset sales and similar covenants and contains customary events of default. The Credit Agreement also contains covenants requiring the Company and its subsidiaries to maintain a maximum (x) consolidated senior net leverage ratio of (i) 3.25:1.00 for the quarter ending September 30, 2025, (ii) 3.25:1.00 for the quarter ending December 31, 2025, (iii) 3.00:1.00 for the quarter ending March 31, 2026, (iv) 2.75:1.00 for the quarter ending June 30, 2026, (v) 2.75:1.00 for the quarter ending September 30, 2026, and (vi) 2.50:1.00 for the quarter ending December 31, 2026 and each fiscal quarter ended thereafter and (y) a fixed charge coverage ratio of 1.20 for the quarter ending September 30, 2025 and each fiscal quarter ended thereafter.

     

    Of the Term Loan, $175,000 is subject to repayment on each of January 1, 2026, April 1, 2026, July 1, 2026 and October 1, 2026 and the remaining balance is to be repaid in the amount of $350,000 beginning January 1, 2027 and the first day of each quarter thereafter. The Term Loan bears interest at a rate equal to the Term SOFR rate plus 8.50%. The Delayed Draw Facility and Incremental Facility, if applicable, shall bear interest following any advance of proceed thereunder, at a rate of either (x) (i) Term SOFR rate plus (ii) 8.5%, or (y) (i) a reference rate equal to the greater of (a) 6.0% per annum, (b) the federal funds rate plus 0.50% per annum, (c) the Term SOFR rate plus 1% per annum, and (d) the rate last quoted by The Wall Street Journal as the “Prime Rate” in the United States, plus (ii) 7.50%.

     

    Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement.

     

    The information under Item 1.01 of this Form 8-K is incorporated by reference into this Item 2.03.

     

    Item 8.01 Other Events.

     

    On June 4, 2025, the Company issued a press release regarding the closing of the Credit Agreement. A copy of the press release is attached as Exhibit 99.1 hereto.

     

    Item 9.01 Financial Statements and Exhibits.‌

     

    (d) Exhibits

     

    Exhibit No.   Description
    10.1 ¥   Credit Agreement, dated as of May 30, 2025, by and among Synergy CHC Corp. as Borrower, each subsidiary of the Borrower listed as a Guarantor therein, the lenders from time-to-time party thereto as Lenders and ACP Agency, LLC, as Collateral Agent and Administrative Agent.
    99.1   Press Release, dated June 4, 2025
    104   Cover Page Interactive Data File (embedded within the inline XBRL document)

     

    ¥Certain schedules and exhibits to this agreement have been omitted in accordance with Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the SEC on request.

    1

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: June 4, 2025  
       
      SYNERGY CHC CORP.
         
      By: /s/ Jack Ross
      Name:  Jack Ross
      Title: Chief Executive Officer

     

     

    2

     

     

    Get the next $SNYR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SNYR

    DatePrice TargetRatingAnalyst
    2/2/2026$5.00Buy
    Ascendiant Capital Markets
    1/21/2025$10.00Buy
    ROTH MKM
    More analyst ratings

    $SNYR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO and Chairman Ross Jack bought $79,578 worth of shares (27,900 units at $2.85), increasing direct ownership by 7% to 410,507 units (SEC Form 4)

    4 - Synergy CHC Corp. (0001562733) (Issuer)

    7/31/25 8:31:46 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    CEO and Chairman Ross Jack bought $29,837 worth of shares (16,100 units at $1.85), increasing direct ownership by 4% to 382,607 units (SEC Form 4)

    4 - Synergy CHC Corp. (0001562733) (Issuer)

    6/11/25 7:17:28 PM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    CEO and Chairman Ross Jack bought $10,870 worth of shares (5,300 units at $2.05), increasing direct ownership by 1% to 366,507 units (SEC Form 4)

    4 - Synergy CHC Corp. (0001562733) (Issuer)

    5/21/25 5:05:31 PM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    $SNYR
    SEC Filings

    View All

    SEC Form EFFECT filed by Synergy CHC Corp.

    EFFECT - Synergy CHC Corp. (0001562733) (Filer)

    12/10/25 12:15:35 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    SEC Form 424B5 filed by Synergy CHC Corp.

    424B5 - Synergy CHC Corp. (0001562733) (Filer)

    12/9/25 4:22:04 PM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    SEC Form S-3 filed by Synergy CHC Corp.

    S-3 - Synergy CHC Corp. (0001562733) (Filer)

    11/26/25 4:41:37 PM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    $SNYR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ascendiant Capital Markets initiated coverage on Synergy CHC Corp. with a new price target

    Ascendiant Capital Markets initiated coverage of Synergy CHC Corp. with a rating of Buy and set a new price target of $5.00

    2/2/26 6:52:55 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    ROTH MKM initiated coverage on Synergy CHC Corp. with a new price target

    ROTH MKM initiated coverage of Synergy CHC Corp. with a rating of Buy and set a new price target of $10.00

    1/21/25 9:10:17 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    $SNYR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Thompson Teresa Brigid

    3 - Synergy CHC Corp. (0001562733) (Issuer)

    10/2/25 9:47:13 PM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    SEC Form 4 filed by President Baumeler Alfred

    4 - Synergy CHC Corp. (0001562733) (Issuer)

    9/22/25 9:31:24 PM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    SEC Form 4 filed by Chief Financial Officer Fickett Jaime

    4 - Synergy CHC Corp. (0001562733) (Issuer)

    9/22/25 9:26:09 PM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    $SNYR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Synergy CHC Corp. (NASDAQ: SNYR) Expands FOCUSfactor® Functional Beverage Distribution Across Canada Through Walmart Canada and McKesson Canada

    WESTBROOK, Maine, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a leading consumer health and wellness company, today announced a major expansion of its FOCUSfactor® functional beverage portfolio across Canada, building on the successful launch of FOCUSfactor's supplement SKUs at Walmart Canada and through McKesson Canada during Q4 2025, with sell-through and consumer feedback supporting category expansion. Beginning in April 2026, Walmart Canada will introduce four additional beverage SKUs, further deepening the brand's presence both in-store and online channels. FOCUSfactor's functional beverage expansion within Walmart Canada will inclu

    1/27/26 8:00:00 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    Synergy CHC Corp. (NASDAQ: SNYR) Appoints Pedro Colmenares as Director of Sales & Marketing for Mexico & Latin America

    WESTBROOK, Maine, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a leading consumer health and wellness company, today announced that Pedro Colmenares has been appointed Director of Sales & Marketing for Mexico & Latin America. In this role, Mr. Colmenares will lead commercial strategy, market expansion, and go-to-market execution across the region. Mr. Colmenares joins the Company at a pivotal time as it advances its international growth strategy. As announced in May 2025, Synergy established a wholly owned subsidiary in Mexico and has begun its initial market entry through shipments of its supplement products to Costco Mexico this week. A

    12/16/25 8:00:00 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    Synergy CHC Corp. (NASDAQ: SNYR) Expands FOCUSfactor Functional Beverage Distribution with Three New Direct Store Delivery Partners Across Maine and Pennsylvania

    WESTBROOK, Maine, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a leading consumer health and wellness company, today announced new Direct Store Delivery (DSD) partnerships with Pine State Beverage, Fuhrer Beverage Company, and Banko Beverage Co. The agreements expand retail distribution of the Company's FOCUSfactor Focus + Energy Ready-to-Drink (RTD) functional beverages and Focus + Energy brain-health shots across Maine and Pennsylvania. Consistent with Synergy's strategy of building a comprehensive nationwide DSD footprint, these new partnerships further strengthen the Company's distribution coverage and reinforce the strong early tract

    12/15/25 8:00:00 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    $SNYR
    Leadership Updates

    Live Leadership Updates

    View All

    Synergy CHC Corp. (NASDAQ: SNYR) Appoints Pedro Colmenares as Director of Sales & Marketing for Mexico & Latin America

    WESTBROOK, Maine, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a leading consumer health and wellness company, today announced that Pedro Colmenares has been appointed Director of Sales & Marketing for Mexico & Latin America. In this role, Mr. Colmenares will lead commercial strategy, market expansion, and go-to-market execution across the region. Mr. Colmenares joins the Company at a pivotal time as it advances its international growth strategy. As announced in May 2025, Synergy established a wholly owned subsidiary in Mexico and has begun its initial market entry through shipments of its supplement products to Costco Mexico this week. A

    12/16/25 8:00:00 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    Synergy CHC (NASDAQ: SNYR) Taps Former Coca-Cola Executive to Lead Strategic Partnerships; Appoints Veteran Costco Buyer to Board of Directors

    Board member Scott Woodburn transitions to Head of Strategic Partnerships to accelerate FOCUSfactor Energy Drink expansion Former Costco Buyer Teresa Thompson brings nearly 40 years of retail expertise in vitamins and supplements WESTBROOK, Maine, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a leading consumer health and wellness company, today announced two key leadership changes: Scott Woodburn has been appointed to Head of Strategic Partnerships to drive the Company's expansion in functional beverages, and Teresa Thompson has been appointed to Synergy's Board of Directors (the "Board"), effective immediately. In connection with Woodb

    9/22/25 8:00:00 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    Synergy CHC (NASDAQ: SNYR) Taps Former Coca-Cola Executive to Help Drive FOCUSfactor Energy Drink Global Expansion

    WESTBROOK, Maine, June 10, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a fast-growing consumer health and wellness company, announced today that Damian Marano has been named Vice President of Beverage, effective immediately. This appointment marks a major milestone in the Company's aggressive push into the booming functional beverage market. "We're excited to welcome Damian to Synergy's executive leadership team," said Jack Ross, CEO of Synergy CHC Corp. "Damian's deep expertise in beverage, CPG, and technology-enabled growth adds another high-caliber industry veteran to further guide our beverage business through its next phase. His proven track

    6/10/25 8:00:00 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    $SNYR
    Financials

    Live finance-specific insights

    View All

    Synergy CHC Corp. Announces Third Quarter 2025 Earnings and Conference Call Information

    WESTBROOK, Maine, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a leading consumer health and wellness company, today announced that it plans to release financial results for the third quarter ended September 30, 2025, on Thursday, November 13, 2025, before the open of market trading. In conjunction with reporting third quarter 2025 results, Synergy will host a conference call at 9:00 a.m. ET / 6:00 a.m. PT with the Company's Chief Executive Officer, Jack Ross, and the Company's Chief Financial Officer, Jaime Fickett. A live webcast of the call will be available on the Investor Relations section of Synergy's website. To access the call by

    10/30/25 4:05:00 PM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    Synergy CHC Corp Reports Second Quarter 2025 Financial Results and its Tenth Consecutive Quarter of Profitability

    WESTBROOK, Maine, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a consumer health and wellness company, is announcing its financial results for the three months ended June 30, 2025. "We are pleased to report another strong quarter, marking our tenth consecutive quarter of profitability," said Jack Ross, CEO of Synergy. "Revenue, gross profit, net income and earnings per share all grew year-over-year, reflecting our continued focus on disciplined execution and profitable growth." "We also made significant progress across our strategic priorities, including expanding the global footprint of our FOCUSfactor brand through a licensing agreemen

    8/14/25 8:00:00 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    Synergy CHC Corp. Announces Second Quarter 2025 Earnings and Conference Call Information

    WESTBROOK, Maine, July 31, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a fast-growing consumer health and wellness company, announced today that it plans to release financial results for the second quarter ended June 30, 2025, on Thursday, August 14, 2025, before the open of market trading. In conjunction with reporting second quarter 2025 results, Synergy will host a conference call at 9:00 a.m. ET / 6:00 a.m. PT with the Company's Chief Executive Officer, Jack Ross, and the Company's Chief Financial Officer, Jaime Fickett. A live webcast of the call will be available on the Investor Relations section of Synergy's website. To access the call by

    7/31/25 4:05:00 PM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    $SNYR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Synergy CHC Corp.

    SC 13D - Synergy CHC Corp. (0001562733) (Subject)

    10/31/24 9:55:58 PM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    SEC Form SC 13G filed by Synergy CHC Corp.

    SC 13G - Synergy CHC Corp. (0001562733) (Subject)

    10/25/24 7:46:44 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care